Feature

Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief


 


Ms. Owen, for one, kept searching for a doctor and eventually found a neurologist willing to certify her to use marijuana and advise her on what to take.

“It’s saved my life,” said the retired university administrative assistant who credited marijuana for weaning her off opioids. “It not only helps my pain, but I can think, walk, and talk again.”

Mary Jo, a Minnesotan, was afraid of being identified as a medical marijuana user, even though she now helps friends navigate the process and it’s legal in her home state.

“There’s still a stigma,” said Mary Jo, who found it effective for treating her pain from a nerve condition. “Nobody helps you figure it out, so you kind of play around with it on your own.”

Still, doctors and scientists worry about the implications of such experimentation.

In a sweeping report last year, the National Academies of Sciences, Engineering and Medicine called on the federal government to support better research, decrying the “lack of definitive evidence on using medical marijuana.”

The national academies’ committee reviewed more than 10,000 scientific abstracts related to the topic. It made 100 conclusions based on its review, including finding evidence that marijuana relieves pain and chemotherapy-induced nausea. But it found “inadequate information” to support or refute effects on Parkinson’s disease.

Yet those who find that medical marijuana helps them can become fierce advocates no matter what their doctors say.

Caryl Barrett, a 54-year-old who lives in Georgia, said she decided to travel out of state to Colorado to treat her pain from her transverse myelitis and the autoimmune disease neurosarcoidosis.

“I realized it worked and I decided to bring it back with me,” she said. “I broke federal law.”

Pages

Recommended Reading

Mortality rate was 10-fold higher in opioid use disorder patients
MDedge Infectious Disease
The latest news on pediatric migraine
MDedge Infectious Disease
‘Chronic Lyme’: Serious bacterial infections reported with unproven treatments
MDedge Infectious Disease
Adjuvant-boosted shingles vaccine earns FDA panel’s unanimous nod
MDedge Infectious Disease
Post-Ebola syndrome includes neurologic sequelae
MDedge Infectious Disease
In close vote, advisory panel prefers Shingrix over Zostavax
MDedge Infectious Disease
Novel herpes zoster vaccine is more cost effective than old vaccine
MDedge Infectious Disease
MDedge Daily News: Why the barber’s chair can help hypertension
MDedge Infectious Disease
MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Infectious Disease
Life and health are not even across the U.S.
MDedge Infectious Disease